Patents Assigned to Taisho Pharmaceutical Co.
-
Patent number: 6613932Abstract: A prostaglandin derivative represented by the formula: [wherein X is CH2, O or S(O)q1, Y is an ethylene group, a vinylene group, an ethynylene group, O(CH2)t1 or S(O)q2(CH2)t1, Z is an ethylene group, a vinylene group or an ethynylene group, R1 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, R2 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-5 alkyl group, a hydroxy-C1-5 alkyl group, a halogeno-C1-5 alkyl group, a C1-5 alkoxy-C1-5 alkyl group, a C2-4 alkoxycarbonyl-C1-5 alkyl group, a carboxyl-C1-5 alkyl group, a cyano-C1-5 alkyl group, a C1-5 alkyl group substituted with a group represented by the formula: —NR7R8, an acyl group, a group represented by the formula: —(CH2)t2CH(NH2)COOR9, etc., and R3 is a hydrogen atom, a C1-10 alkyl group, etc.], a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: March 11, 2002Date of Patent: September 2, 2003Assignees: Taisho Pharmaceutical Co., Ltd., Fumie SatoInventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi, Hitomi Hirano
-
Patent number: 6600038Abstract: Carbamoyl tetrahydropyridine derivatives represented by the formula: [in the formula, R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C5 alkyl group, or the like; Y1-Y2 represents (R4)C═C(R5), (R6)C═N, N═N, (R7)N—CO, or N═C(R8); X1, X2, and X3 are identical or different, and each represents a hydrogen atom, a halogen atom, or the like; R3, R4, R5, and R6 are identical or different, and each represents a hydrogen atom or an alkyl group; R7 represents a hydrogen atom, a C1-C5 alkyl group, or the like; and R8 represents a hydrogen atom or a carbamoyl group] or a pharmaceutically acceptable salt thereof, and intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF.Type: GrantFiled: August 30, 2001Date of Patent: July 29, 2003Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Toshihito Kumagai, Kazuyuki Tomisawa
-
Patent number: 6558700Abstract: A multiple-unit sustained release tablet characterized by consisiting of a granular part and a powdery part, each granule comprising a matrix composed of a water-insoluble polymer and an active ingredient. Another tablet characterized in that each granule is coated with a release-controlling film. The object of the present invention is to provide a multiple-unit sustained release tablet showing little change in dissolution speed caused by the compression in the tableting step.Type: GrantFiled: October 17, 2000Date of Patent: May 6, 2003Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Kazutaka Tsuchida, Shinji Aoki
-
Publication number: 20030033853Abstract: Problem:Type: ApplicationFiled: August 20, 2002Publication date: February 20, 2003Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Kazumi Osada, Kunio Yamazaki, Gary K. Beauchamp
-
Patent number: 6500958Abstract: The present invention relates to compounds which are useful for efficient synthesis of 2-amino-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acids. The compounds according to the present invention comprise 2-oxobicyclo[3.1.Type: GrantFiled: June 24, 2002Date of Patent: December 31, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Toshihito Kumagai, Kazunari Sakagami, Kazuyuki Tomisawa
-
Patent number: 6491942Abstract: The present invention provides a suppository comprising a hydrophobic hydroxypropyl methylcellulose. The present invention is useful as a suppository base which has little interaction with a drug and has an excellent retainability.Type: GrantFiled: April 26, 2001Date of Patent: December 10, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Tomoko Fujimori, Kimiko Sugita
-
Patent number: 6482990Abstract: A prostaglandin analog represented by Formula (I): [wherein A is an ethylene group, a vinylene group or an ethynylene group, Y1 and Y2 are the same or different, and each a hydrogen atom, a halogen atom, a cyano group, —CONR3R4 (wherein R3 and R4 are the same or different, and each a hydrogen atom or a C1-6 alkyl group, or R3 and R4 together with the nitrogen atom to which they are attached form a C4-8 cyclic amine), a C1-3 aminoalkyl group, a C1-6 hydroxyalkyl group, NR5R6 (wherein R5 and R6 are the same or different, and each a hydrogen atom or a C1-6 alkyl group), a hydroxyl group, a C1-6 alkoxy group, a C1-9 alkyl group, a C1-6 alkyl group substituted with halogen(s), a C1-5 acyl group or COOR7 (wherein R7 is a hydrogen atom, a C1-6 alkyl group or a phenyl group), R1 and R2 are the same or different, and each a hydrogen atom, a halogen atom, a C1-9 alkyl group or a C1-6 alkyl group substituted with halogen(s), m is an integer of 0 to 6, and n is an integer of 0 to 3], a pType: GrantFiled: March 4, 2002Date of Patent: November 19, 2002Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi
-
Patent number: 6479674Abstract: The present invention relates to compounds which are useful for efficient synthesis of 2-amino-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acids. The compounds according to the present invention comprise 2-oxobicyclo[3.1.Type: GrantFiled: September 24, 2001Date of Patent: November 12, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Toshihito Kumagai, Kazunari Sakagami, Kazuyuki Tomisawa
-
Patent number: 6476056Abstract: An aryloxyaniline derivative represented by the formula: wherein Ar1 and Ar2 are the same or different, and are each a substituted or unsubstituted phenyl group, a substituted or unsubstituted pyridyl group or a naphthyl group, provided that Ar1 and Ar2 are not both phenyl or both naphthyl and are not phenyl and naphthyl, R1 is a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, an alkoxy group having 1 to 10 carbon atoms, a substituted or unsubstituted phenyl group or a group of the formula: —NR2(R3) (wherein R2 and R3 are the same or different, and are each a hydrogen atom or an alkyl group having 1 to 10 carbon atoms, X1 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a phenoxy group, a halogen atom, a trifluoromethyl group, a carbamoyl group or an aminosulfonyl group, Y1 is a branched or unbranched alkylene group having 1 to 6 carbon atoms or a single bond; and pharmaceutically acceptablType: GrantFiled: August 7, 2001Date of Patent: November 5, 2002Assignees: Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Toshio Nakamura, Shigeyuki Chaki, Kazuyuki Tomisawa, Masashi Nagamine, Kenji Yamamoto, Koichiro Harada, Masanori Yoshida
-
Patent number: 6471944Abstract: Powdery aerosol preparations, which are characterized in that 50 to 90% by weight of a propellant having a vapor pressure at 20° C. of 4.5 kg/cm2 or less, 5 to 30% by weight of an aliphatic hydrocarbon having a boiling point of 5 to 40° C., 0.5 to 20% by weight of a powdery component and 1 to 20% by weight of a lower alcohol are packed in a container provided with a straight nozzle button having an orifice of 0.7 to 2.0 mm, show improved adhesion of the powders and the active ingredients to the skin and give an excellent feel in using, are provided.Type: GrantFiled: January 27, 2000Date of Patent: October 29, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Tsuyoshi Uchiyama, Megumi Suzuki, Ariko Imaoji
-
Publication number: 20020156299Abstract: The present invention relates to compounds which are useful for efficient synthesis of 2-amino-4-oxobicyclo[3.1.0]hexane-2,6-dicarboxylic acids.Type: ApplicationFiled: June 24, 2002Publication date: October 24, 2002Applicant: TAISHO PHARMACEUTICAL CO., LTD.Inventors: Atsuro Nakazato, Toshihito Kumagai, Kazunari Sakagami, Kazuyuki Tomisawa
-
Patent number: 6455584Abstract: To provide a prostaglandin derivative represented by the formula: wherein A is an ethylene group, a vinylene group, an ethynylene group, O(CH2)q or S(O)r(CH2)q, R1 is a C3-10 cycloalkyl group, a C1-4 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-4 alkyl group, a C1-10 alkyl group, a C1-10 alkyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkenyl group, a C2-10 alkenyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkynyl group, a C2-10 alkynyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s) or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 5, n is an integer of 1 to 4, p is 0, 1 or 2, q is an integer of 1 to 5 and r is 0, 1 or 2; a pharmaceutically acceptable salt thereof or a hydrate thereof exhibit excellent action in inhibiting the growth of vascular smooth muscle and is useful as a drug for inhibition of restenosis after perType: GrantFiled: January 4, 2002Date of Patent: September 24, 2002Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi, Hitomi Hirano
-
Patent number: 6407121Abstract: The present invention provides an arylpiperidine derivative of the formula (I) or a pharmaceutically acceptable salt thereof, which has antipsychotic effect: wherein D is a carbon atom or a nitrogen atom, E is a CH group or a nitrogen atom, G is an oxygen atom, a sulfur atom, a nitrogen atom or an NH group, Y1 is a hydrogen atom or a halogen atom, n is an integer of 1 to 4, and R1 is a group represented by any of the formulas (i) to (iv) defined in the specification.Type: GrantFiled: September 13, 2000Date of Patent: June 18, 2002Assignees: Nihon Nohyaku Co., Ltd., Taisho Pharmaceutical Co., Ltd.Inventors: Masashi Nagamine, Makoto Gotoh, Masanori Yoshida, Atsuro Nakazato, Toshihito Kumagai, Shigeyuki Chaki, Kazuyuki Tomisawa
-
Patent number: 6395786Abstract: A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH2)m, a cis-vinylene group or a phenylene group, Z is an ethylene group, a trans-vinylene group, OCH2 or S(O)nCH2, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 3, and n is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.Type: GrantFiled: November 27, 2000Date of Patent: May 28, 2002Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Kazuya Kameo, Kenji Yamada, Shigeru Okuyama, Naoya Ono
-
Patent number: 6392086Abstract: The present inventions relate to a (1S,5R,6S)- or (1SR, 5RS, 6SR)-3-fluoro-2-oxobicyclo[3.1.0]hex-3-ene-6-carboxylic acid derivative represented by Formula (1): [in the formula, R represents OR1 or NR1R2, wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a (C3-C6 cycloalkyl) (C1-C6 alkyl) group, an aryl group, an aryl (C1-C6 alkyl) group, a (C1-C6 alkoxy) (C1-C6 alkyl) group, a C1-C6 hydroxyalkyl group, a (C1-C6 alkylthio) (C1-C6 alkyl) group, or a C1-C6 mercaptoalkyl group], and a process for producing the same, and a process for efficiently producing a fluorine-containing amino acid compound acting on group 2 metabotropic glutamate receptors, which has treatment effects or prevention effects on psychiatric diseases or neurological diseases, characterized by hydrogenating the derivative, and subsequently, subjecting it to hydantoination or aminocyanidation, followed by hydrolysis.Type: GrantFiled: June 7, 2001Date of Patent: May 21, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Atsuro Nakazato, Toshihito Kumagai, Kazunari Sakagami, Kazuyuki Tomisawa, Hisanako Ito, Takeo Taguchi
-
Patent number: 6380384Abstract: A 1,2-dihydro-2-oxoquinoline derivative represented by the formula: wherein Ar is a pyridyl group or a group represented by the formula: (wherein X3 and X4 are the same or different, and are each a hydrogen atom, a halogen atom, a C1-5 alkyl group, a C1-5 alkoxy group, a hydroxyl group or a trifluoromethyl group), Y is a nitrogen atom, CH or C(OH), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom; or X1 and X2 taken together form an alkylenedioxy group, and n is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 10, 2001Date of Patent: April 30, 2002Assignees: Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Toshihito Kumagai, Shigeyuki Chaki, Kazuyuki Tomisawa, Masashi Nagamine, Makoto Gotoh, Masanori Yoshida
-
Patent number: 6355663Abstract: This invention provides a substituted isoxazolylthiophene compound represented by the formula wherein R1 and R2 individually represent an alkyl group of 1-5 carbon atoms, R3 represents a cyano group or a group CONR5R6 (in which R5 and R6 individually represent a hydrogen atom or an alkyl group of 1-10 carbon atoms), R4 represents an alkyl group of 1-5 carbon atoms or a phenyl group, and n is an integer of 0-2, or a salt thereof. The compounds of the invention are useful for the treatment or prevention of various bone diseases or nerve diseases, because they specifically enhance the action of the cell differentiation induction factors found in a living body.Type: GrantFiled: March 1, 2001Date of Patent: March 12, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masahiro Harada, Junko Takeda, Toshio Nakamura, Shiuji Saito
-
Patent number: 6355266Abstract: A transdermal absorption preparation containing &agr;-form crystals of indomethacin in a vehicle. The present invention aims to provide an indomethacin-containing transdermal absorption preparation increased in the percutaneous absorption of indomethacin from the preparation, and improved in the stability of indomethacin in the preparation.Type: GrantFiled: April 14, 2000Date of Patent: March 12, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Tomohiro Ohtsuki, Chikako Kiuchi, Yoshiko Yoshino
-
Patent number: 6342590Abstract: Erythromycin A derivatives represented by the general formula wherein R1 is a 2-alkenyl group having 3 to 15 carbon atoms, an arylmethyl group, or an arylmethyl group substituted by 1 to 3 of a halogen atom, an alkoxy group 1 to 4 carbon atoms, a nitro group or an alkoxycarbonyl group having 2 to 6 carbon atoms, R2 is a substituted silyl group and R3 is a hydrogen atom or R2, are disclosed. These compounds are useful as intermediates of the anti-bacterial agents.Type: GrantFiled: April 14, 1992Date of Patent: January 29, 2002Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Shigeo Morimoto, Takashi Adachi, Tohru Matsunaga, Masato Kashimura, Yoshiaki Watanabe, Kaoru Sota
-
Patent number: 6333358Abstract: An aryloxyaniline derivative represented by the formula: wherein Ar1 and Ar2 are each a substituted or unsubstituted phenyl group, pyridyl group or naphthyl group, R1 is a hydrogen atom, an alkyl group, etc., X1 is a hydrogen atom, an alkyl group, etc., y1 is a branched or unbranched alkylene group having 1 to 6 carbon atoms or a single bond; or a pharmaceutically acceptable salt thereof can provide medicines having a high affinity for MDR, and therefore, exhibiting a therapeutic or preventive effect on anxiety, related diseases thereto, depression, etc.Type: GrantFiled: February 1, 2000Date of Patent: December 25, 2001Assignees: Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd.Inventors: Atsuro Nakazato, Taketoshi Okubo, Toshio Nakamura, Shigeyuki Chaki, Kazuyuki Tomisawa, Masashi Nagamine, Kenji Yamamoto, Koichiro Harada, Masanori Yoshida